15% OFF YOUR FIRST ORDER · CODE 1stOrder
Research hub

Vilon Peptide

Vilon is a synthetic dipeptide of L-lysine and L-glutamic acid studied in thymic cell, immune, and tissue biology research.

DipeptideL-Lysyl-L-glutamic acidLysylglutamic acid
Molecular Weight
275.3 g/mol
Molecular Formula
C11H21N3O5
CAS Number
45234-02-4
Purity
98.2%
Available nowVilon Peptide · in stock, EU dispatch
Vilon Peptide Vial
20mg
Price range: $47.39 through $58.61View
01

What Is Vilon Peptide?

Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid, with the sequence Lys-Glu (KE). Its chemical name is L-lysyl-L-glutamic acid. PubChem lists Vilon as a synonym for lysylglutamic acid and classifies it as a dipeptide.

In the published literature, Vilon is identified as L-Lys-L-Glu (Lys-Glu). The compound is therefore chemically defined as a two-amino-acid peptide rather than a longer peptide or protein.

02

Research Overview Table

Research OverviewCurrent Status
Compound ClassSynthetic dipeptide (L-Lys-L-Glu)
Primary Research TargetNo single validated molecular target established
Published Cell StudiesAvailable
Published Animal StudiesAvailable
Primary Research FieldCellular and molecular biology
Research MaturityPreclinical
Intended UseResearch and laboratory use only
03

Chemical and Molecular Characteristics

Chemical NameL-Lysyl-L-glutamic acid
Compound NameVilon
Compound TypeSynthetic dipeptide
Molecular FormulaC₁₁H₂₁N₃O₅
Molecular Weight275.3 g/mol
Purity98.2%
CAS Number45234-02-4
Batch / Lot NumberP260711-3-LR062002
Primary Research TargetNo single validated molecular target established
Product Format(s)Lyophilized vial
Physical PresentationWhite to almost white powder

Certificates:

CoAhttps://iceland.direct-sarms.com/wp-content/uploads/2026/09/VIP_COA.pdf
HPLChttps://iceland.direct-sarms.com/wp-content/uploads/2026/09/Vilon_HPLC.pdf
04

Mechanism of Action Under Investigation

Published research has not established a specific receptor, enzyme, or direct molecular binding target for Vilon (Lys-Glu). One study reported that Vilon increased sphingomyelinase activity in thymocyte membranes and associated its effects with the sphingomyelin signal-transduction pathway. However, the study did not demonstrate direct interaction between Vilon and sphingomyelinase.

Another study reported that Vilon affected interleukin-2 (IL-2) mRNA synthesis. But this finding does not establish the molecular interaction responsible for the change. Therefore, the direct target of Vilon and the biochemical sequence connecting the peptide to these signaling changes remain unresolved in the published literature.

05

Scientific Research Context

Vilon (Lys-Glu) has been described in research examining cellular and tissue processes. Studies have used cultured cells, organotypic cultures and animal experiments to examine biological responses to the dipeptide. The published work covers cellular function, gene expression, and tissue-related changes. Most of the available evidence comes from in vitro experiments and preclinical studies in animals. These studies provide the main experimental basis for the current scientific literature on Vilon.

06

Vilon Biology and Biological Pathways

01

Primary Biological Function

The published literature does not establish a defined physiological function for Vilon. Research has examined its association with cellular proliferation, differentiation, gene expression, and enzyme activity. These observations have mainly involved thymic and immune-related cells, as well as other tissues examined in experimental studies.

02

Relevant Metabolic or Signalling Pathways

Published research has examined Vilon in relation to sphingomyelin signaling, with one study reporting increased sphingomyelinase activity following Vilon exposure. Other research examined changes in IL-2 expression and the expression and protein synthesis of SIRT1, PARP1, and PARP2. These findings provide experimental evidence for changes in cellular signaling and gene regulation, but do not establish a defined Vilon-specific signaling pathway.

03

Tissue-Specific Biology

Vilon research has examined the thymus, spleen, small intestine, and heart. Studies have also investigated Vilon in cultured thymic cells and splenic tissue cultures. In the small intestine, research examined enzyme activity in epithelial and subepithelial layers. A separate study examined gene expression in mouse heart tissue.

04

Experimental Biomarkers

Published Vilon studies have measured sphingomyelinase activity, IL-2 mRNA expression, SIRT1, PARP1, and PARP2 gene expression, and protein synthesis. Other biochemical endpoints reported in Vilon research include maltase, alkaline phosphatase, and glycyl-L-leucine dipeptidase activity.

05

Laboratory Investigation Methods

Published Vilon research has used DNA microarray analysis to measure changes in gene expression. Other studies have used gene-expression and protein-synthesis measurements to examine SIRT1, PARP1, and PARP2. Biochemical assays have also been used to measure enzyme activity, including sphingomyelinase and intestinal digestive enzymes.

07

Experimental Models Used in Published Research

Published Vilon studies have used cultured cells, organotypic tissue cultures, and animal models. The main limitations of these models are the use of isolated cells, ex vivo tissue conditions, and biological differences between experimental animals and humans.

01

Cell Culture Models

Published Vilon studies have used mouse thymocytes and splenocytes, as well as cultured human thymocytes and thymic epithelial cells. The limitation of these models is that cultured cells are studied outside their normal tissue environment, so they cannot fully reproduce the cellular interactions and physiological conditions present in intact tissue.

02

Organotypic Culture Models

Vilon has been investigated using organotypic cultures of rat spleen explants, including tissue obtained from rats aged 3 days, 3 weeks and 2 years. The limitation of this model is that the explanted tissue is maintained outside the animal, so it does not reproduce whole-body physiological conditions or systemic interactions.

03

Rat Models

Published Vilon research has used Wistar rats, including intact animals and rats exposed to whole-body gamma irradiation. The main limitation is that these are species specific models, so physiological differences between rats and humans limit direct translation of findings to human biology.

04

Mouse Models

CBA mice were used in a published Vilon study examining the compound. The study identifies the animals as female CBA mice. The limitation is that this is a single inbred mouse strain, so findings from this model cannot be directly generalized to other strains or human biology.

08

Published Research

01

Thymocyte Proliferation and Sphingomyelin Signaling

Studies examined Vilon in relation to thymocyte blast transformation, proliferation, interleukin-1β comitogenic activity, and sphingomyelin signaling. Sphingomyelinase activity was also measured as part of this research.

02

IL-2 Gene Expression

Published Vilon studies examined IL-2 gene expression and IL-2 mRNA synthesis. The research assessed Vilon's effects on IL-2 expression and examined how the response varied with peptide concentration and treatment duration.

03

Intestinal Enzyme Activity

Published studies examined digestive enzyme activity associated with Vilon, including invertase, maltase, alkaline phosphatase, aminopeptidases and dipeptidases. Further research examined maltase, alkaline phosphatase, and glycyl-L-leucine dipeptidase activity in epithelial, stromal and seromuscular intestinal layers.

04

Aging-Related Changes

Vilon has been investigated in relation to biological age, lifespan, physical activity, endurance, body temperature, reproductive function, free-radical processes, and spontaneous neoplasms. Other research examined Vilon-associated changes in thymus and spleen during accelerated aging.

05

Chromatin and Heterochromatin

Published studies examined structural and facultative heterochromatin, nucleolar organizer regions, ribosomal gene activity and chromatin deheterochromatinization. Research also examined age-related changes in chromatin organization and Vilon's effects on chromatin structure.

06

Reactive Oxygen Species

Research examined Vilon in relation to reactive oxygen species and free-radical processes, including ROS generation in mitochondrial and cytosolic fractions. Other in-vitro work examined lipid peroxidation and intracellular reactive oxygen species.

07

Experimental Neoplasia

Studies investigated Vilon in relation to experimental neoplasia, including spontaneous tumors and chemically induced urinary bladder and other neoplastic changes. The published research examined tumor development and changes associated with Vilon exposure.

08

SIRT1, PARP1, and PARP2 Expression

Published research examined SIRT1, PARP1 and PARP2 gene expression and protein synthesis in relation to Vilon (KE peptide). The study specifically evaluated these changes during replicative aging and also investigated possible interactions between the peptide and DNA sequences located in the promoters of these genes.

09

Limitations of Current Research

01

Evidence Is Predominantly Preclinical

The Vilon literature includes substantial experimental research, but much of it is based on cellular, tissue and animal studies. Human clinical studies are also reported, but they represent a smaller portion of the published evidence.

02

Human Clinical Evidence

The available human studies are limited in number and scope. Published clinical research has focused mainly on immune status, blood coagulation, fibrinolysis, and related blood parameters, rather than broad clinical outcomes.

03

Species Differences

Much of the Vilon literature involves non human experimental systems. Biological differences between experimental species and humans can affect cellular responses, gene regulation, metabolism, and tissue biology. Findings from these studies therefore cannot be assumed to apply directly to human biology.

04

Study Design Limitations

Differences in experimental conditions, measured endpoints, and study protocols limit direct comparison across the Vilon literature. The studies also examine different biological outcomes, making it difficult to determine whether findings from separate investigations are consistent.

05

Independent Replication

The published Vilon studies do not provide enough independent replication to establish how consistently individual findings can be reproduced across different research groups.

06

Long-Term Evidence

The published literature includes some long-term observations, but long term evidence remains limited. Available studies do not provide enough evidence to characterize Vilon effects across different durations, outcomes, and populations.

10

Analytical Documentation

HPLC provides a chromatographic profile of a material and allows purity to be assessed from the separated components. It is commonly used for routine quality testing and batch analysis.

LC-MS adds mass measurement to chromatographic separation. This combination can help confirm molecular identity and distinguish the target compound from related substances or degradation products.

NMR examines the behavior of atomic nuclei in a magnetic field. The resulting spectra can provide information about molecular structure and composition when this technique is appropriate.

A Certificate of Analysis (CoA) brings together the documented results of analytical testing for a particular batch. Such records help establish the identity, purity, and quality of material used in laboratory work. Analytical documentation verifies product identity and quality, not biological performance.

11

Storage and Laboratory Handling

Store Vilon from Direct Sarms Iceland at −20°C to 8°C under the specified product conditions. Keep the material protected when not in use and avoid unnecessary exposure to unsuitable storage conditions.

Handle Vilon in a clean laboratory environment to reduce the risk of contamination and preserve sample integrity. Use appropriate laboratory equipment and established handling practices. Qualified laboratory personnel should carry out all handling procedures and maintain suitable conditions throughout laboratory work.

12

Why Researchers Choose Direct SARMs?

Direct SARMs Iceland is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Iceland, we aim to make the research supply process simple, clear, and reliable.

13

Frequently asked questions

Vilon is a dipeptide composed of L-lysine and L-glutamic acid, also written as Lys-Glu or L-lysyl-L-glutamic acid. PubChem lists Vilon as a synonym for lysylglutamic acid, and published research identifies Vilon as a dipeptide.
14

Why choose us?

Direct SARMs Iceland is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Iceland, we aim to make the research supply process simple, clear, and reliable.

Vilon Peptide is supplied solely for laboratory research and analytical purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or any clinical application. Information provided on this page is for scientific reference only and should be considered alongside the cited primary literature and relevant analytical documentation.
Available now

Vilon Peptide from Direct Sarms Iceland

Vilon Peptide Vial
20mg
Price range: $47.39 through $58.61View